Inventing new therapies without reinventing the wheel: the power of drug repurposing

British Journal of Pharmacology

Volumn 175, Issue 2, 2018, Pages 165-167

  Papapetropoulos, Andreas ^a,b   Szabo, Csaba ^c  

^a UNIVERSITY OF ATHENS   (Greece)

^b BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^c University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GABAPENTIN; METHOTREXATE; MINOXIDIL; PREGABALIN; ROPINIROLE; THALIDOMIDE;

CLINICAL PRACTICE; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG MARKETING; DRUG MECHANISM; DRUG REPOSITIONING; DRUG TARGETING; EDITORIAL; HUMAN; NONHUMAN; OFF LABEL DRUG USE; PRIORITY JOURNAL; PROCEDURES; TRENDS;

DRUG REPOSITIONING; HUMANS;

EID: 85044646894     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.14081     Document Type: Editorial

References (30)

1. Ahmad A, Olah G, Herndon DN, Szabo C (2018). The clinically used PARP inhibitor olaparib improves organ function, suppresses inflammatory responses and accelerates wound healing in a murine model of third-degree burn injury. Br J Pharmacol 175: 232–245.
2. Barratt MJ, Frail DE (eds) (2012). Drug repositioning: bringing new life to shelved assets and existing drugs. John Wiley & Sons, Hoboken, NJ.
3. Berger NA, Besson VC, Boulares AH, Bürkle A, Chiarugi A, Clark RS et al. (2018). Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases. Br J Pharmacol 175: 192–222.
4. Bertolini F, Sukhatme VP, Bouche G (2015). Drug repurposing in oncology – patient and health systems opportunities. Nat Rev Clin Oncol 12: 732–742.
5. Bombardo M, Malagola E, Chen R, Rudnicka A, Graf R, Sonda S (2018). Ibuprofen and diclofenac treatments reduce proliferation of pancreatic acinar cells upon inflammatory injury and mitogenic stimulation. Br J Pharmacol 175: 335–347.
6. Cha Y, Erez T, Reynolds IJ, Kumar D, Ross J, Koytiger G et al. (2018). Drug repurposing from the perspective of pharmaceutical companies. Br J Pharmacol 175: 168–180.
7. Cheng F, Liu C, Jiang J, Lu W, Li W, Liu G et al. (2012). Prediction of drug-target interactions and drug repositioning via network-based inference. PLoS Comput Biol 8: e1002503.
8. Cichonska A, Rousu J, Aittokallio T (2015). Identification of drug candidates and repurposing opportunities through compound-target interaction networks. Expert Opin Drug Discov 10: 1333–1345.
9. Deftereos SN, Andronis C, Friedla EJ, Persidis A, Persidis A (2011). Drug repurposing and adverse event prediction using high-throughput literature analysis. Wiley Interdiscip Rev Syst Biol Med 3: 323–334.
10. Ishida J, Konishi M, Ebner N, Springer J (2016). Repurposing of approved cardiovascular drugs. J Transl Med 14: 269.
11. Issa NT, Byers SW, Dakshanamurthy S (2013). Drug repurposing: translational pharmacology, chemistry, computers and the clinic. Curr Top Med Chem 13: 2328–2336.
12. Jin G, Wong STC (2014). Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines. Drug Discov Today 19: 637–644.
13. Kola I, Landis J (2013). How can attrition rates be reduced in cancer drug discovery? Expert Opin Drug Discov 8: 363–368.
14. Korkmaz-Icöz S, Radovits T, Szabó G (2018a). Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury and for treating heart failure. Br J Pharmacol 175: 223–231.
15. Korkmaz-Icöz S, Szczesny B, Marcatti M, Li S, Ruppert M, Lasitschka F et al. (2018b). Olaparib protects cardiomyocytes against oxidative stress and improves graft contractility during the early phase after heart transplantation in rats. Br J Pharmacol 175: 246–261.
16. Krishnan V, Ma YL, Chen CZ, Thorne N, Bullock H, Tawa G et al. (2018). Repurposing a novel parathyroid hormone analogue to treat hypoparathyroidism. Br J Pharmacol 175: 262–271.
17. López-García I, Gerő D, Szczesny B, Szoleczky P, Olah G, Módis K et al. (2018). Development of a stretch-induced neurotrauma model for medium-throughput screening in vitro: identification of rifampicin as a neuroprotectant. Br J Pharmacol 175: 284–300.
18. Mullard A (2016). Parsing clinical success rates. Nat Rev Drug Discov 15: 447.
19. Muzzi M, Gerace E, Buonvicino D, Coppi E, Resta F, Formentini L et al. (2018). Dexpramipexole improves bioenergetics and outcome in experimental stroke. Br J Pharmacol 175: 272–283.
20. Nagy L, Márton J, Vida A, Kis G, Bokor E, Kun S et al. (2018). Glycogen phosphorylase inhibition improves beta cell function. Br J Pharmacol 175: 301–319.
21. Naylor S, Kauppi D, Schonfeld JM. (2015). Therapeutic drug repurposing, repositioning, and rescue: part II – business review. Drug Discov Spring: 57–72.
22. Nosengo N (2016). New tricks for old drugs. Nature 534: 314–316.
23. Novac N (2013). Challenges and opportunities of drug repositioning. Trends Pharmacol Sci 175: 262–271.
24. Scannell JW, Blanckley A, Boldon H, Warrington B (2012). Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov 11: 191–200.
25. Sharlow ER (2016). Revisiting repurposing. Assay Drug Dev Technol 14: 554–556.
26. Smith RB (2011). Repositioned drugs: integrating intellectual property and regulatory strategy. Drug Discov Today 8: 131–137.
27. Sternitzke C (2014). Drug repurposing and the prior art patents of competitors. Drug Discov Today 19: 1841–1847.
28. Varga ZV, Matyas C, Erdelyi K, Cinar R, Nieri D, Chicca A et al. (2018). β-Caryophyllene protects against alcoholic steatohepatitis by attenuating inflammation and metabolic dysregulation in mice. Br J Pharmacol 175: 320–334.
29. Waring MJ, Arrowsmith J, Leach AR, Leeson PD, Mandrell S, Owen RM et al. (2015). An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nat Rev Drug Discov 14: 475–486.
30. Zheng W, Sun W, Simeonov A (2018). Drug repurposing screens and synergistic drug-combinations for infectious diseases. Br J Pharmacol 175: 181–191.